Certara, Inc. (CERT) Stock Analysis
Healthcare · Health Information Services · NasdaqGS
Certara, Inc. (CERT) posted $418.84M in revenue for fiscal 2025 (up 8.7% year over year), with a net loss of $1.59M, and has compounded revenue about 11.5%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Certara, Inc.
Certara, Inc. has grown revenue from $208.51M to $418.84M over the last 7 fiscal years, compounding about 11.5% a year. The most recent year was up 8.7%, so growth has cooled from its longer-run pace.
Net margin sits at -0.4%, up 2.7 points year over year. It carries about $293.09M of total debt.
At today's valuation the market is pricing in roughly -4.2% annual free-cash-flow growth — versus the 16.6% it actually delivered over the last five years, so the price is arguably undemanding against what it has already proven. The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Certara, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Certara, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $208.51M | $243.53M | $286.10M | $335.64M | $354.34M | $385.15M | $418.84M |
| Gross profit | $128.74M | $142.76M | $174.49M | $203.07M | $213.31M | — | — |
| Net income | $-8.93M | $-49.40M | $-13.27M | $14.73M | $-55.36M | $-12.05M | $-1.59M |
| Net margin | -4.3% | -20.3% | -4.6% | 4.4% | -15.6% | -3.1% | -0.4% |
Source: Certara, Inc. SEC filings (10-K).
Certara, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -0.4%).
What growth is priced into CERT stock?
At today's market cap of $802.71M, Certara, Inc. is priced for free-cash-flow growth of about -4.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $94.56M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 16.6%/yr over the last five fiscal years and revenue 11.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 7 years of Certara, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CERT in your portfolio →
Certara, Inc. financial history by metric
Compare Certara, Inc. with peers
About Certara, Inc.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Certara, Inc. — frequently asked questions
What is Certara, Inc.'s revenue?
Certara, Inc. (CERT) reported revenue of $418.84M for fiscal year 2025, up 8.7% from the prior year, according to its SEC filings.
Is Certara, Inc. profitable?
No — CERT reported a net loss of $-1.59M in fiscal 2025.
What is CERT's P/E ratio?
Certara, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Certara, Inc. growing?
CERT's revenue grew at roughly 11.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Certara, Inc. have?
As of fiscal year 2025, CERT carried roughly $293.09M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Certara, Inc.'s market cap?
Certara, Inc. (CERT) has a market capitalization of about $802.71M, based on the latest data in our nightly-refreshed cache.
When does Certara, Inc.'s fiscal year end?
CERT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into CERT stock?
At today's market cap of $802.71M, Certara, Inc. is priced for free-cash-flow growth of about -4.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $94.56M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 16.6%/yr over the last five fiscal years and revenue 11.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Certara, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.